Skip Navigation


Rheumatology Advance Access originally published online on November 3, 2006
Rheumatology 2006 45(12):1575-1576; doi:10.1093/rheumatology/kel369
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/12/1575    most recent
kel369v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Williams, E. L.
Right arrow Articles by Edwards, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, E. L.
Right arrow Articles by Edwards, C. J.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTERS TO THE EDITOR

Patient preferences in choosing anti-TNF therapies-R1

E. L. Williams and C. J. Edwards

Department of Rheumatology, Southampton University Hospitals NHS Trust, Southampton SO166YD, UK

Correspondence to: Dr E. Williams, BSc MRCP, Senior House Officer, Department of Rheumatology, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK. E-mail: emwilliams25@btinternet.co.uk

The first 10% of the full text of this article appears below.

SIR, There are now three different anti-TNF agents licenced for use in patients with rheumatoid arthritis refractory to treatment with conventional DMARDs. Several other novel therapies including selective co-stimulation modulators (abatacept) [1], an antibody to IL-6 receptors (MRA), monoclonal antibodies against IL-15, and anti-CD20 antibodies (rituxumab) are being developed [2]. Preliminary data suggest that these other therapies may provide further alternatives to conventional DMARDs over the next few years [1, 2]. This plethora of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Journal of Rheumatology SupplementHome page
A. THOMPSON
Practical Aspects of Therapeutic Intervention in Rheumatoid Arthritis
J Rheumatol Suppl, June 1, 2009; 82(0): 39 - 41.
[Abstract] [Full Text] [PDF]